Arikawa Yasuyoshi, Hasuoka Atsushi, Nishida Haruyuki, Hirase Keizo, Inatomi Nobuhiro, Takagi Terufumi, Tarui Naoki, Kawamoto Makiko, Imanishi Akio, Itoh Fumio, Kajino Masahiro
Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi-2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd, 26-1, Muraokahigashi-2-chome, Fujisawa, Kanagawa 251-8555, Japan.
Bioorg Med Chem Lett. 2015;25(10):2037-40. doi: 10.1016/j.bmcl.2015.03.094. Epub 2015 Apr 6.
On the basis of a series of novel and potent potassium-competitive acid blockers represented by 1-sulfonylpyrrole derivative 7, we prepared several five-membered heterocyclic analogues (8) and evaluated their H(+),K(+)-ATPase activities in vitro. We also assessed the role of the methylaminomethyl side chain by comparison with methylamino and ethylamino derivatives. We observed that the five-membered core ring and its orientation affect inhibitory activity and that the methylaminomethyl moiety is the best side chain. On the basis of potency and ligand-lipophilicity efficiency, compound 7 remains the most drug-like of the compounds studied to date. This study revealed the factors necessary for potent H(+),K(+)-ATPase inhibition, such as differences in electron density, the properties of the lone pair at each apical position of the heteroaromatic ring, and the geometry of the substituents.
基于以1-磺酰基吡咯衍生物7为代表的一系列新型强效钾竞争性酸阻滞剂,我们制备了几种五元杂环类似物(8),并在体外评估了它们的H⁺,K⁺-ATP酶活性。我们还通过与甲氨基和乙氨基衍生物比较,评估了甲基氨基甲基侧链的作用。我们观察到五元核心环及其取向影响抑制活性,并且甲基氨基甲基部分是最佳侧链。基于效力和配体-亲脂性效率,化合物7仍然是迄今为止所研究化合物中最具药物样性的。这项研究揭示了强效抑制H⁺,K⁺-ATP酶所需的因素,例如电子密度的差异、杂芳环每个顶端位置孤对电子的性质以及取代基的几何形状。